International Stem Cell (ISCO) Other Non-Current Liabilities (2011 - 2020)
International Stem Cell (ISCO) posted quarterly Other Non-Current Liabilities of $40000.0 for Q3 2020, down 80.68% quarter-over-quarter from $207000.0 in Q4 2019.
International Stem Cell (ISCO) Other Non-Current Liabilities (2011 - 2020) Analysis & Trends
International Stem Cell (ISCO) has reported Other Non-Current Liabilities for 9 consecutive years, with $40000.0 the latest figure, recorded in Q3 2020.
- In Q3 2020, Other Non-Current Liabilities changed N/A year-over-year to $40000.0; the TTM figure through Sep 2020 stood at $40000.0 (changed N/A YoY), while the FY2019 annual figure was $207000.0, down 88.14% from the prior year.
- Other Non-Current Liabilities eased to $40000.0 in Q3 2020 per ISCO's latest filing, from $207000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $19.6 million in Q1 2016 and bottomed at $40000.0 in Q3 2020.
- Historically, Other Non-Current Liabilities has averaged $3.7 million across 5 years, with a median of $2.6 million in 2017.
- Annual changes were most pronounced in 2016 — Other Non-Current Liabilities surged 755.65% — and 2019, when it plunged 88.14%.
- International Stem Cell's Other Non-Current Liabilities stood at $2.0 million in 2016, then jumped by 52.22% to $3.1 million in 2017, then slumped by 43.94% to $1.7 million in 2018, then slumped by 88.14% to $207000.0 in 2019, then slumped by 80.68% to $40000.0 in 2020.
- Business Quant data shows ISCO's Other Non-Current Liabilities at $40000.0 in Q3 2020, $207000.0 in Q4 2019, and $837000.0 in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | International Stem Cell | 4.32 Mn | 3.23 Mn | 1.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 40,000.00 |
| Dec 31, 2019 | 207,000.00 |
| Jun 30, 2019 | 837,000.00 |
| Mar 31, 2019 | 1.15 Mn |
| Dec 31, 2018 | 1.75 Mn |
| Sep 30, 2018 | 2.02 Mn |
| Jun 30, 2018 | 2.78 Mn |
| Mar 31, 2018 | 2.76 Mn |
| Dec 31, 2017 | 3.11 Mn |
| Sep 30, 2017 | 3.67 Mn |
| Jun 30, 2017 | 2.49 Mn |
| Mar 31, 2017 | 4.08 Mn |
| Dec 31, 2016 | 2.05 Mn |
| Sep 30, 2016 | 5.42 Mn |
| Jun 30, 2016 | 7.15 Mn |
| Mar 31, 2016 | 19.62 Mn |
| Dec 31, 2015 | 239,000.00 |
| Sep 30, 2015 | 1.35 Mn |
| Jun 30, 2015 | 1.65 Mn |
| Mar 31, 2015 | 3.36 Mn |